UK Renal Registry, Bristol, UK.
Nephron Clin Pract. 2013;125(1-4):139-69. doi: 10.1159/000360027. Epub 2014 Feb 14.
These analyses examine: a) survival from the start of renal replacement therapy (RRT); b) survival amongst all prevalent dialysis patients alive on 31st December 2011; c) the cause of death for incident and prevalent patients and d) the projected life years remaining for patients starting RRT. Changes in survival between the 1997 and 2011 cohort are also reported.
Survival was calculated for both incident and prevalent patients on RRT. Survival of incident patients (starting RRT during 2011) was calculated both from the start of RRT and from 90 days after starting RRT, both with and without censoring at transplantation. Prevalent dialysis patients were censored at transplantation. Both Kaplan-Meier and Cox adjusted models were used to calculate survival. The relative risk of death was calculated and compared with the UK general population.
The unadjusted 1 year after 90 day survival for patients starting RRT in 2011 was 87.5%, representing an increase from the previous year (87.3%). The age-adjusted one year survival (adjusted to age 60) of prevalent dialysis patients increased from 88.2% in the 2002 cohort to 89.7% in the 2011 cohort. Prevalent diabetic patient one year survival rose from 81.6% in the 2002 cohort to 84.9% in the 2011 cohort. The age-standardised mortality ratio for prevalent RRT patients compared with the general population was 16.6 for age group 35-39 and 2.7 at age 85+ years. In the prevalent RRT dialysis population, cardiovascular disease accounted for 22% of deaths, infection 17% and treatment withdrawal 19%. The median life years remaining for a 25-29 year old on RRT was 18.5 years and approximately 2.5 for a 75+ year old.
Survival of patients starting RRT has improved in the 2011 incident cohort. The relative risk of death on RRT compared with the general population has fallen since 2001.
本分析研究了:a)开始接受肾脏替代治疗(RRT)后的生存率;b)2011 年 12 月 31 日仍存活的所有现患透析患者的生存率;c)发病和现患患者的死亡原因;d)开始接受 RRT 的患者的预期剩余寿命。还报告了 1997 年和 2011 年队列之间生存情况的变化。
对接受 RRT 的现患和新发患者的生存率进行了计算。新发患者(2011 年开始接受 RRT)的生存率,既从 RRT 开始时计算,也从 RRT 开始后 90 天时计算,均包括和不包括移植时的删失。现患透析患者在移植时被删失。均采用 Kaplan-Meier 和 Cox 调整模型来计算生存率。计算死亡的相对风险,并与英国一般人群进行比较。
2011 年开始接受 RRT 的患者在接受 RRT 后 90 天的 1 年生存率为 87.5%,比前一年(87.3%)有所提高。调整到 60 岁年龄后的现患透析患者 1 年生存率从 2002 年队列的 88.2%上升到 2011 年队列的 89.7%。现患糖尿病患者 1 年生存率从 2002 年队列的 81.6%上升到 2011 年队列的 84.9%。与一般人群相比,现患 RRT 患者的年龄标准化死亡率为 35-39 岁年龄组为 16.6,85 岁以上年龄组为 2.7。在现患 RRT 透析患者人群中,心血管疾病占死亡人数的 22%,感染占 17%,治疗退出占 19%。25-29 岁开始接受 RRT 的患者的中位剩余寿命为 18.5 年,75 岁以上患者的中位剩余寿命约为 2.5 年。
2011 年新发患者队列中开始接受 RRT 的患者的生存率有所提高。与 2001 年相比,RRT 患者的死亡相对风险已经下降。